Shinichi Sato

List of Publications by Year in Descending Order

210 papers	6,085 citations	40 h-index	71 g-index
225 ext. papers	7,124 ext. citations	4 avg, IF	5.47 L-index

#	Paper	IF	Citations
210	Decrease in MAP3Ks expression enhances the cell death caused by hyperthermia.. *International Journal of Hyperthermia*, **2022**, 39, 200-208	3.7	1
209	Predictors of Rituximab Effect on Modified Rodnan Skin Score in Systemic Sclerosis: a machine learning analysis of the DESIRES trial.. *Rheumatology*, **2022**,	3.9	1
208	Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis.. *International Journal of Hematology*, **2022**, 1	2.3	0
207	Serum C-X-C Chemokine Ligand 1 Levels in Patients with Systemic Sclerosis: Relationship of Clinical and Laboratory Observations to Anti-CD20 Monoclonal Antibody Administration. *Life*, **2022**, 12, 646	3	1
206	Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis. *International Journal of Rheumatic Diseases*, **2021**, 24, 260-267	2.3	1
205	Endothelial CCR6 expression due to FLI1 deficiency contributes to vasculopathy associated with systemic sclerosis. *Arthritis Research and Therapy*, **2021**, 23, 283	5.7	1
204	The contribution of LIGHT to the development of systemic sclerosis by modulating IL-6 and Th1 chemokine expression in dermal fibroblasts. *Journal of Investigative Dermatology*, **2021**,	4.3	1
203	Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. *Nature Communications*, **2021**, 12, 5947	17.4	3
202	HMGB1-mediated chromatin remodeling attenuates gene expression for the protection from allergic contact dermatitis. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	3
201	Development of a prediction model of treatment response in patients with cutaneous arteritis: Insights from a cohort of 33 patients. *Journal of Dermatology*, **2021**, 48, 1021-1026	1.6	0
200	Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis. *International Journal of Rheumatic Diseases*, **2021**, 24, 711-718	2.3	4
199	Rapidly progressive interstitial lung disease associated with dermatomyositis：longitudinal course of anti-MDA5 antibody titer in two cases. *Journal of Cutaneous Immunology and Allergy*, **2021**, 4, 78-82	0.3	
198	Serum vasohibin-1 levels: A potential marker of dermal and pulmonary fibrosis in systemic sclerosis. *Experimental Dermatology*, **2021**, 30, 951-958	4	1
197	Fli1 deficiency suppresses RALDH1 activity of dermal dendritic cells and related induction of regulatory T cells: a possible role in scleroderma. *Arthritis Research and Therapy*, **2021**, 23, 137	5.7	2
196	Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency. *Scientific Reports*, **2021**, 11, 11617	4.9	1
195	Dermatomyositis-like eruptions and fasciitis with novel compound heterozygous MEFV mutations: Newly recognized features of a variant of familial Mediterranean fever. *Journal of Dermatology*, **2021**, 48, 1453-1456	1.6	
194	Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. *Lancet Rheumatology, The*, **2021**, 3, e489-e497	14.2	20

193	Serum S100A12 levels: Possible association with skin sclerosis and interstitial lung disease in systemic sclerosis. *Experimental Dermatology*, **2021**, 30, 409-415	4	3
192	Fibrosarcomatous dermatofibrosarcoma protuberans in a seven-year-old boy. *European Journal of Dermatology*, **2021**, 31, 106-107	0.8	
191	A potential contribution of decreased serum galectin-10 levels to systemic inflammation and pulmonary vascular involvement in systemic sclerosis. *Experimental Dermatology*, **2021**, 30, 959-965	4	1
190	CD147-Cyclophilin a Interactions Promote Proliferation and Survival of Cutaneous T-Cell Lymphoma. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
189	B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis. *Arthritis and Rheumatology*, **2021**, 73, 2086-2095	9.5	2
188	Expert-Level Distinction of Systemic Sclerosis from Hand Photographs Using Deep Convolutional Neural Networks. *Journal of Investigative Dermatology*, **2021**, 141, 2536-2539	4.3	0
187	Case of systemic sclerosis with multiple primary malignancies in whom anti-RNA polymerase III antibody was detected by immunoprecipitation. *Journal of Dermatology*, **2020**, 47, e269-e270	1.6	0
186	Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease. *Journal of Dermatology*, **2020**, 47, 796-800	1.6	2
185	Decreased serum cathepsin S levels in patients with systemic sclerosis-associated interstitial lung disease. *Journal of Dermatology*, **2020**, 47, 1027-1032	1.6	2
184	Altered Properties of Endothelial Cells and Mesenchymal Stem Cells Underlying the Development of Scleroderma-like Vasculopathy in KLF5 ;Fli-1 Mice. *Arthritis and Rheumatology*, **2020**, 72, 2136-2146	9.5	7
183	Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. *Journal of Dermatology*, **2020**, 47, 483-489	1.6	8
182	Subacute thyroiditis in psoriasis patients treated with biologics targeting tumor necrosis factor-α and interleukin-17A, a report of two cases. *Journal of Cutaneous Immunology and Allergy*, **2020**, 3, 33-34	0.3	2
181	Regulation of skin fibrosis by RALDH1-producing dermal dendritic cells via retinoic acid-mediated regulatory T cell induction: A role in scleroderma. *Journal of Dermatological Science*, **2020**, 97, 125-134	4.3	3
180	Clinical significance of endothelial vasodilatory function evaluated by EndoPAT in patients with systemic sclerosis. *Journal of Dermatology*, **2020**, 47, 609-614	1.6	3
179	A case of folliculotropic mycosis fungoides successfully treated with topical steroid treatment. *Journal of Cancer Research and Therapeutics*, **2020**, 16, 196-198	1.2	
178	Tumoral calcinosis in systemic lupus erythematosus associated with fat necrosis. *Journal of Dermatology*, **2020**, 47, e134-e135	1.6	1
177	Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis. *Rheumatology*, **2020**, 59, 2005-2015	3.9	3
176	Characteristics of Japanese patients with eosinophilic fasciitis: A brief multicenter study. *Journal of Dermatology*, **2020**, 47, 1391-1394	1.6	1

175	Association of functional (GA)n microsatellite polymorphism in the FLI1 gene with susceptibility to human systemic sclerosis. *Rheumatology*, **2020**, 59, 3553-3562	3.9	4
174	YKL-40 Promotes Proliferation of Cutaneous T-Cell Lymphoma Tumor Cells through Extracellular Signal-Regulated Kinase Pathways. *Journal of Investigative Dermatology*, **2020**, 140, 860-868.e3	4.3	5
173	Increased IL-26 Expression Promotes T Helper Type 17- and T Helper Type 2-Associated Cytokine Production by Keratinocytes in Atopic Dermatitis. *Journal of Investigative Dermatology*, **2020**, 140, 636-644.e2	4.3	17
172	Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies. *International Heart Journal*, **2020**, 61, 413-418	1.8	4
171	Overlapping systemic sclerosis and sarcoidosis with mutually exclusive disease activities: a case report and analysis of previous studies. *European Journal of Dermatology*, **2020**, 30, 50-52	0.8	
170	Metabolome Analysis Reveals Dermal Histamine Accumulation in Murine Dermatitis Provoked by Genetic Deletion of P-Glycoprotein and Breast Cancer Resistance Protein. *Pharmaceutical Research*, **2019**, 36, 158	4.5	3
169	IL-10-producing regulatory B cells in skin diseases. *Journal of Cutaneous Immunology and Allergy*, **2019**, 2, 68-74	0.3	2
168	Keratinocyte Proline-Rich Protein Deficiency in Atopic Dermatitis Leads to Barrier Disruption. *Journal of Investigative Dermatology*, **2019**, 139, 1867-1875.e7	4.3	5
167	Possible association of decreased serum CXCL14 levels with digital ulcers in patients with systemic sclerosis. *Journal of Dermatology*, **2019**, 46, 584-589	1.6	3
166	Facile fabrication of PEG-coated PLGA microspheres via SPG membrane emulsification for the treatment of scleroderma by ECM degrading enzymes. *Colloids and Surfaces B: Biointerfaces*, **2019**, 179, 453-461	6	4
165	Cyclophosphamide Pulse Therapy Normalizes Vascular Abnormalities in a Mouse Model of Systemic Sclerosis Vasculopathy. *Journal of Investigative Dermatology*, **2019**, 139, 1150-1160	4.3	1
164	A potential contribution of decreased galectin-7 expression in stratified epithelia to the development of cutaneous and oesophageal manifestations in systemic sclerosis. *Experimental Dermatology*, **2019**, 28, 536-542	4	13
163	Novel topical and systemic therapies in atopic dermatitis. *Immunological Medicine*, **2019**, 42, 84-93	3.7	15
162	Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma. *Journal of Dermatological Science*, **2019**, 96, 134-142	4.3	4
161	Association of NCF1 polymorphism with systemic lupus erythematosus and systemic sclerosis but not with ANCA-associated vasculitis in a Japanese population. *Scientific Reports*, **2019**, 9, 16366	4.9	9
160	Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. *Journal of Dermatology*, **2019**, 46, 1006-1013	1.6	24
159	A case of concurrent psoriasis and ulcerative colitis with development of arthritis during adalimumab treatment. *European Journal of Dermatology*, **2019**, 29, 651-653	0.8	0
158	A case of papuloerythroderma secondary to crusted scabies. *Journal of Cutaneous Immunology and Allergy*, **2019**, 2, 174-175	0.3	

157	Prevention of calpain-dependent degradation of STK38 by MEKK2-mediated phosphorylation. *Scientific Reports*, **2019**, 9, 16010	4.9	4
156	Increased expression of aquaporin-1 in dermal fibroblasts and dermal microvascular endothelial cells possibly contributes to skin fibrosis and edema in patients with systemic sclerosis. *Journal of Dermatological Science*, **2019**, 93, 24-32	4.3	7
155	Association between serum autotaxin or phosphatidylserine-specific phospholipase A1 levels and melanoma. *Journal of Dermatology*, **2018**, 45, 571-579	1.6	16
154	Diagnostic criteria, severity classification and guidelines of localized scleroderma. *Journal of Dermatology*, **2018**, 45, 755-780	1.6	35
153	Diagnostic criteria, severity classification and guidelines of systemic sclerosis. *Journal of Dermatology*, **2018**, 45, 633-691	1.6	16
152	Serum Soluble CD48 Levels as a Prognostic Marker in Mycosis Fungoides and Sézary Syndrome. *Journal of Investigative Dermatology*, **2018**, 138, 2286-2288	4.3	2
151	Exacerbated Immune Complex-Mediated Vascular Injury in Mice with Heterozygous Deficiency of Aryl Hydrocarbon Receptor through Upregulation of FcγReceptor III Expression on Macrophages. *Journal of Investigative Dermatology*, **2018**, 138, 2195-2204	4.3	1
150	Impact of a new simplified disability scoring system for adult patients with localized scleroderma. *Journal of Dermatology*, **2018**, 45, 431-435	1.6	2
149	Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide. *Journal of Dermatology*, **2018**, 45, e140-e141	1.6	2
148	Systemic sclerosis complicated with localized scleroderma-like lesions induced by Köbner phenomenon. *Journal of Dermatological Science*, **2018**, 89, 282-289	4.3	11
147	Variants at HLA-A, HLA-C, and HLA-DQB1 Confer Risk of Psoriasis Vulgaris in Japanese. *Journal of Investigative Dermatology*, **2018**, 138, 542-548	4.3	29
146	TBX4 is involved in the super-enhancer-driven transcriptional programs underlying features specific to lung fibroblasts. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2018**, 314, L177-L191	5.8	26
145	CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis. *Experimental Dermatology* , **2018**, 27, 1030-1037	4	27
144	Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease. *Journal of Dermatology*, **2018**, 45, 1221-1224	1.6	5
143	Gastroesophageal Reflux Disease-Related Disorders of Systemic Sclerosis Based on the Analysis of 66 Patients. *Digestion*, **2018**, 98, 201-208	3.6	5
142	Fli1-haploinsufficient dermal fibroblasts promote skin-localized transdifferentiation of Th2-like regulatory T cells. *Arthritis Research and Therapy*, **2018**, 20, 23	5.7	13
141	An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis. *Scientific Reports*, **2018**, 8, 11843	4.9	24
140	Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. *Journal of Dermatology*, **2018**, 45, 881-890	1.6	21

139	Decreased IL-10-producing regulatory B cells in patients with advanced mycosis fungoides. *European Journal of Dermatology*, **2018**, 28, 314-319	0.8	2
138	Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study. *Journal of Dermatology*, **2018**, 45, 1425-1433	1.6	15
137	Progranulin overproduction due to constitutively activated c-Abl/PKC-δ/Fli1 pathway contributes to the resistance of dermal fibroblasts to the anti-fibrotic effect of tumor necrosis factor-α in localized scleroderma. *Journal of Dermatological Science*, **2018**, 92, 207-214	4.3	4
136	Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma. *Blood*, **2018**, 132, 1922-1935	2.2	23
135	Linear immunoglobulin A bullous dermatosis limited to oral mucosa associated with ulcerative colitis. *Journal of Dermatology*, **2018**, 45, e281-e282	1.6	0
134	Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma. *Journal of Experimental Medicine*, **2017**, 214, 1129-1151	16.6	58
133	CXCL17 Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-Derived Suppressor Cells and Regulatory T Cells. *Journal of Immunology*, **2017**, 198, 3897-3908	5.3	27
132	Serum H-ficolin levels: Clinical association with interstitial lung disease in patients with systemic sclerosis. *Journal of Dermatology*, **2017**, 44, 1168-1171	1.6	6
131	Fli1 Deficiency Induces CXCL6 Expression in Dermal Fibroblasts and Endothelial Cells, Contributing to the Development of Fibrosis and Vasculopathy in Systemic Sclerosis. *Journal of Rheumatology*, **2017**, 44, 1198-1205	4.1	15
130	Case of mycosis fungoides with gastric and central nervous system involvement. *Journal of Dermatology*, **2017**, 44, e166-e167	1.6	
129	Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis. *Journal of Dermatology*, **2017**, 44, 967-971	1.6	12
128	Systemic Sclerosis Dermal Fibroblasts Suppress Th1 Cytokine Production via Galectin-9 Overproduction due to Fli1 Deficiency. *Journal of Investigative Dermatology*, **2017**, 137, 1850-1859	4.3	26
127	Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis. *Arthritis and Rheumatology*, **2017**, 69, 1879-1890	9.5	28
126	The impact of transcription factor Fli1 deficiency on the regulation of angiogenesis. *Experimental Dermatology*, **2017**, 26, 912-918	4	16
125	Twelve-week, multicenter, placebo-controlled, randomized, double-blind, parallel-group, comparative phase II/III study of benzoyl peroxide gel in patients with acne vulgaris: A secondary publication. *Journal of Dermatology*, **2017**, 44, 774-782	1.6	6
124	Increased Interleukin-19 Expression in Cutaneous T-cell Lymphoma and Atopic Dermatitis. *Acta Dermato-Venereologica*, **2017**, 97, 1172-1177	2.2	15
123	Placental Growth Factor and Vascular Endothelial Growth Factor Together Regulate Tumour Progression via Increased Vasculature in Cutaneous T-cell Lymphoma. *Acta Dermato-Venereologica*, **2017**, 97, 586-592	2.2	12
122	A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis. *Archives of Dermatological Research*, **2017**, 309, 833-842	3.3	6

121	Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis. *Journal of Investigative Dermatology*, **2017**, 137, 631-640	4.3	21
120	Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease. *Modern Rheumatology*, **2017**, 27, 618-622	3.3	4
119	Circulating galectin-1 concentrations in systemic sclerosis: potential contribution to digital vasculopathy. *International Journal of Rheumatic Diseases*, **2016**, 19, 622-7	2.3	12
118	Thymic Stromal Chemokine TSLP Acts through Th2 Cytokine Production to Induce Cutaneous T-cell Lymphoma. *Cancer Research*, **2016**, 76, 6241-6252	10.1	57
117	Hematopoietic stem cell transplantation for cutaneous T-cell lymphoma: Summary of 11 cases from two facilities in Japan and Brazil. *Journal of Dermatology*, **2016**, 43, 638-42	1.6	11
116	Association of anti-RNA polymerase III antibody and silicone breast implants in patients with systemic sclerosis. *Journal of Dermatology*, **2016**, 43, 808-10	1.6	8
115	A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis. *Experimental Dermatology*, **2016**, 25, 287-92	4	17
114	Tamibarotene Ameliorates Bleomycin-Induced Dermal Fibrosis by Modulating Phenotypes of Fibroblasts, Endothelial Cells, and Immune Cells. *Journal of Investigative Dermatology*, **2016**, 136, 387-398	4.3	18
113	Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells. *Annals of the Rheumatic Diseases*, **2016**, 75, 1858-65	2.4	11
112	Effect of ambrisentan on peripheral circulation in patients with systemic sclerosis. *Modern Rheumatology*, **2016**, 26, 454-7	3.3	1
111	Human Leukocyte Antigen and Systemic Sclerosis in Japanese: The Sign of the Four Independent Protective Alleles, DRB1*13:02, DRB1*14:06, DQB1*03:01, and DPB1*02:01. *PLoS ONE*, **2016**, 11, e0154255	3.7	17
110	Autoimmunity in Systemic Sclerosis: Overview **2016**, 21-37		
109	A case of penile basal cell carcinoma reconstructed by scrotal myofasciocutaneous flap. *Dermatologic Therapy*, **2016**, 29, 349-352	2.2	1
108	Serum levels of interleukin-18-binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosis. *Journal of Dermatology*, **2016**, 43, 912-8	1.6	9
107	Decreased interleukin-21 expression in skin and blood in advanced mycosis fungoides. *Journal of Dermatology*, **2016**, 43, 819-22	1.6	4
106	Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis. *Rheumatology*, **2015**, 54, 1308-16	3.9	34
105	Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis. *Arthritis and Rheumatology*, **2015**, 67, 254-65	9.5	49
104	Elevated serum galectin-9 levels in patients with atopic dermatitis. *Journal of Dermatology*, **2015**, 42, 723-6	1.6	11

103	Regulatory B cells in human inflammatory and autoimmune diseases: from mouse models to clinical research. *International Immunology*, **2015**, 27, 495-504	4.9	68
102	CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis. *Journal of Dermatology*, **2015**, 42, 613-5	1.6	33
101	Endothelin receptor blockade ameliorates vascular fragility in endothelial cell-specific Fli-1-knockout mice by increasing Fli-1 DNA binding ability. *Arthritis and Rheumatology*, **2015**, 67, 1335-44	9.5	25
100	Vasculopathy in scleroderma. *Seminars in Immunopathology*, **2015**, 37, 489-500	12	105
99	Progranulin Overproduction Due to Fli-1 Deficiency Contributes to the Resistance of Dermal Fibroblasts to Tumor Necrosis Factor in Systemic Sclerosis. *Arthritis and Rheumatology*, **2015**, 67, 3245-55	9.5	24
98	Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 15136-41	11.5	39
97	Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. *Arthritis and Rheumatology*, **2015**, 67, 517-26	9.5	67
96	Abnormal B lymphocyte activation and function in systemic sclerosis. *Annals of Dermatology*, **2015**, 27, 1-9	0.4	28
95	Deficiency of both L-selectin and ICAM-1 exacerbates imiquimod-induced psoriasis-like skin inflammation through increased infiltration of antigen presenting cells. *Clinical Immunology*, **2015**, 157, 43-55	9	13
94	A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis. *Experimental Dermatology*, **2015**, 24, 127-32	4	37
93	Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation. *Oncotarget*, **2015**, 6, 18081-93	3.3	30
92	TLR4, rather than TLR2, regulates wound healing through TGF-□and CCL5 expression. *Journal of Dermatological Science*, **2014**, 73, 117-24	4.3	64
91	Skin barrier dysfunction and low antimicrobial peptide expression in cutaneous T-cell lymphoma. *Clinical Cancer Research*, **2014**, 20, 4339-48	12.9	22
90	Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. *Journal of Dermatology*, **2014**, 41, 418-20	1.6	19
89	An association study of 36 psoriasis susceptibility loci for psoriasis vulgaris and atopic dermatitis in a Japanese population. *Journal of Dermatological Science*, **2014**, 76, 156-7	4.3	10
88	Effects of the immunosuppressant rapamycin on the expression of human □2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts. *Journal of Dermatological Science*, **2014**, 74, 251-9	4.3	22
87	Genetic polymorphism in the TRAF3IP2 gene is associated with psoriasis vulgaris in a Japanese population. *Journal of Dermatological Science*, **2014**, 73, 264-5	4.3	8
86	Serum autotaxin levels correlate with pruritus in patients with atopic dermatitis. *Journal of Investigative Dermatology*, **2014**, 134, 1745-1747	4.3	17

85	The role of IL-32 in cutaneous T-cell lymphoma. *Journal of Investigative Dermatology*, **2014**, 134, 1428-1435	6.5	40
84	Serum levels of angiopoietin-2, but not angiopoietin-1, are elevated in patients with erythrodermic cutaneous T-cell lymphoma. *Acta Dermato-Venereologica*, **2014**, 94, 9-13	2.2	14
83	Clinical correlation of brachial artery flow-mediated dilation in patients with systemic sclerosis. *Modern Rheumatology*, **2014**, 24, 106-11	3.3	20
82	Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. *Nature Communications*, **2014**, 5, 5797	17.4	98
81	Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis. *Journal of Dermatology*, **2014**, 41, 746-8	1.6	5
80	Novel IL36RN gene mutation revealed by analysis of 8 Japanese patients with generalized pustular psoriasis. *Journal of Dermatological Science*, **2014**, 76, 267-9	4.3	15
79	Cilostazol improves lymphatic function by inducing proliferation and stabilization of lymphatic endothelial cells. *Journal of Dermatological Science*, **2014**, 74, 150-8	4.3	15
78	Animal models of scleroderma: current state and recent development. *Current Rheumatology Reports*, **2013**, 15, 382	4.9	23
77	Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis. *Archives of Dermatological Research*, **2013**, 305, 17-23	3.3	13
76	ICAM-1 deficiency exacerbates sarcoid-like granulomatosis induced by Propionibacterium acnes through impaired IL-10 production by regulatory T cells. *American Journal of Pathology*, **2013**, 183, 1731-1739	5.8	9
75	Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation. *Journal of Leukocyte Biology*, **2013**, 94, 563-73	6.5	71
74	CXCR4 negatively regulates keratinocyte proliferation in IL-23-mediated psoriasiform dermatitis. *Journal of Investigative Dermatology*, **2013**, 133, 2530-2537	4.3	15
73	Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. *Rheumatology*, **2013**, 52, 790-9	3.9	34
72	Exogenous application of hydrogen sulfide donor attenuates inflammatory reactions through the L-selectin-involved pathway in the cutaneous reverse passive Arthus reaction. *Journal of Leukocyte Biology*, **2013**, 93, 573-84	6.5	6
71	Delayed wound healing due to increased interleukin-10 expression in mice with lymphatic dysfunction. *Journal of Leukocyte Biology*, **2013**, 94, 137-45	6.5	19
70	Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis. *Modern Rheumatology*, **2013**, 23, 323-329	3.3	19
69	Anti-laminin □1 pemphigoid accompanied by autoantibodies to laminin □3 and □2 subunits of laminin-332. *JAMA Dermatology*, **2013**, 149, 1437-9	5.1	5
68	Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis. *Modern Rheumatology*, **2013**, 23, 884-890	3.3	14

67	Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis. *Modern Rheumatology*, **2013**, 23, 323-9	3.3	11
66	A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. *PLoS ONE*, **2012**, 7, e32272	3.7	31
65	Proteasome inhibitor bortezomib ameliorates intestinal injury in mice. *PLoS ONE*, **2012**, 7, e34587	3.7	10
64	Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma. *Archives of Dermatological Research*, **2012**, 304, 401-6	3.3	14
63	Increased serum levels of soluble CD163 in patients with scleroderma. *Clinical Rheumatology*, **2012**, 31, 1059-64	3.9	28
62	Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma. *Acta Dermato-Venereologica*, **2012**, 92, 282-3	2.2	48
61	Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma. *Journal of Investigative Dermatology*, **2012**, 132, 1280-9	4.3	21
60	Lymphatic dysfunction impairs antigen-specific immunization, but augments tissue swelling following contact with allergens. *Journal of Investigative Dermatology*, **2012**, 132, 667-76	4.3	16
59	Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity. *Modern Rheumatology*, **2012**, 22, 668-675	3.3	26
58	P2Y6 receptor signaling pathway mediates inflammatory responses induced by monosodium urate crystals. *Journal of Immunology*, **2012**, 188, 436-44	5.3	62
57	IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. *American Journal of Pathology*, **2011**, 178, 735-43	5.8	138
56	Serum CCL23 levels are increased in patients with systemic sclerosis. *Archives of Dermatological Research*, **2011**, 303, 29-34	3.3	15
55	Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. *Clinical Rheumatology*, **2011**, 30, 825-30	3.9	91
54	Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis. *Clinical Rheumatology*, **2011**, 30, 921-5	3.9	23
53	A portable dermatoscope for easy, rapid examination of periungual nailfold capillary changes in patients with systemic sclerosis. *Rheumatology International*, **2011**, 31, 1601-6	3.6	17
52	The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. *Arthritis and Rheumatism*, **2011**, 63, 3086-97		30
51	Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. *Arthritis and Rheumatism*, **2011**, 63, 3575-85		60
50	Significant attenuation of macrovascular involvement by bosentan in a patient with diffuse cutaneous systemic sclerosis with multiple digital ulcers and gangrene. *Modern Rheumatology*, **2011**, 21, 548-552	3.3	13

49	The development of Th1-mediated sarcoidosis improves the clinical course of Th2-mediated atopic dermatitis. *Modern Rheumatology*, **2011**, 21, 406-409	3.3	4
48	Disseminated cutaneous and visceral Kaposi sarcoma in a patient with rheumatoid arthritis receiving corticosteroids and tacrolimus. *Modern Rheumatology*, **2011**, 21, 309-312	3.3	3
47	Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation. *Annals of the Rheumatic Diseases*, **2011**, 70, 194-200	2.4	46
46	Significant attenuation of macrovascular involvement by bosentan in a patient with diffuse cutaneous systemic sclerosis with multiple digital ulcers and gangrene. *Modern Rheumatology*, **2011**, 21, 548-52	3.3	7
45	Kunihiko Tamaki, M.D., Ph.D., Emeritus Professor, University of Tokyo, 1946–2010. *Journal of Dermatology*, **2010**, 37, 777-779	1.6	1
44	The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses. *Journal of Leukocyte Biology*, **2010**, 88, 117-22	6.5	23
43	Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. *Journal of Immunology*, **2010**, 184, 4801-9	5.3	242
42	Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. *Journal of Immunology*, **2010**, 185, 2502-15	5.3	103
41	Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis. *Rheumatology*, **2010**, 49, 2375-80	3.9	26
40	Bortezomib: a promising treatment for inflammatory diseases. *International Journal of Clinical Rheumatology*, **2010**, 5, 513-514	1.5	
39	Studies on 1-(2-phenethyl)-4-(N-propionylanilino)piperidine (fentanyl) and related compounds VII. Quantification of alpha-methylfentanyl metabolites excreted in rat urine. *Forensic Science International*, **2010**, 195, 68-72	2.6	16
38	Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. *Arthritis and Rheumatism*, **2010**, 62, 2476-87		100
37	Increased serum pentraxin 3 in patients with systemic sclerosis. *Journal of Rheumatology*, **2009**, 36, 976-83	4.1	37
36	Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. *Journal of Clinical Immunology*, **2009**, 29, 180-9	5.7	83
35	CD19, a response regulator of B lymphocytes, regulates wound healing through hyaluronan-induced TLR4 signaling. *American Journal of Pathology*, **2009**, 175, 649-60	5.8	65
34	Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?. *Journal of Dermatological Science*, **2008**, 50, 240-2	4.3	100
33	CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. *American Journal of Pathology*, **2008**, 172, 1650-63	5.8	165
32	Increased Serum Soluble OX40 in Patients with Systemic Sclerosis. *Journal of Rheumatology*, **2008**, 35, 2359-2362	4.1	44

31	Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity. *Journal of Rheumatology*, **2008**, 35, 1825-9	4.1	23
30	BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. *Journal of Investigative Dermatology*, **2007**, 127, 2772-80	4.3	58
29	Intercellular adhesion molecule-1 deficiency attenuates the development of skin fibrosis in tight-skin mice. *Journal of Immunology*, **2007**, 179, 698-707	5.3	32
28	Phase-dependent roles of E-selectin during chronic contact hypersensitivity responses. *American Journal of Pathology*, **2007**, 170, 1649-58	5.8	12
27	CD19 expression in B cells is important for suppression of contact hypersensitivity. *American Journal of Pathology*, **2007**, 171, 560-70	5.8	92
26	Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. *Arthritis and Rheumatism*, **2006**, 54, 192-201		202
25	E- and P-selectins synergistically inhibit bleomycin-induced pulmonary fibrosis. *American Journal of Pathology*, **2006**, 169, 740-9	5.8	13
24	Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. *Journal of Rheumatology*, **2006**, 33, 275-84	4.1	101
23	P-selectin glycoprotein ligand-1 is required for the development of cutaneous vasculitis induced by immune complex deposition. *Journal of Leukocyte Biology*, **2004**, 76, 374-82	6.5	14
22	Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. *Arthritis and Rheumatism*, **2004**, 50, 1918-27		223
21	Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. *Arthritis and Rheumatism*, **2004**, 50, 4002-7		69
20	Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. *Molecular Immunology*, **2004**, 41, 1123-33	4.3	99
19	Relative contributions of selectins and intercellular adhesion molecule-1 to tissue injury induced by immune complex deposition. *American Journal of Pathology*, **2003**, 162, 1463-73	5.8	32
18	L-selectin or ICAM-1 deficiency reduces an immediate-type hypersensitivity response by preventing mast cell recruitment in repeated elicitation of contact hypersensitivity. *Journal of Immunology*, **2003**, 170, 4325-34	5.3	50
17	The cutaneous reverse Arthus reaction requires intercellular adhesion molecule 1 and L-selectin expression. *Journal of Immunology*, **2002**, 168, 2970-8	5.3	41
16	Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis. *American Journal of Pathology*, **2002**, 161, 1607-18	5.8	48
15	CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. *Journal of Clinical Investigation*, **2002**, 109, 1453-1462	15.9	159
14	CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. *Journal of Clinical Investigation*, **2002**, 109, 1453-62	15.9	63

13	Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. *Journal of Dermatological Science*, **2001**, 27, 140-6	4.3	216
12	Quantitative genetic variation in CD19 expression correlates with autoimmunity. *Journal of Immunology*, **2000**, 165, 6635-43	5.3	255
11	Delayed wound healing in the absence of intercellular adhesion molecule-1 or L-selectin expression. *American Journal of Pathology*, **2000**, 157, 237-47	5.8	132
10	Abnormalities of adhesion molecules and chemokines in scleroderma. *Current Opinion in Rheumatology*, **1999**, 11, 503-507	5.3	29
9	Elevated soluble CD23 levels in the sera from patients with localized scleroderma. *Archives of Dermatological Research*, **1996**, 288, 74-8	3.3	17
8	Soluble CD4 and CD8 in serum from patients with localized scleroderma. *Archives of Dermatological Research*, **1996**, 288, 358-62	3.3	30
7	Elevated soluble CD23 levels in the sera from patients with localized scleroderma **1996**, 288, 74		2
6	Soluble CD4 and CD8 in serum from patients with localized scleroderma **1996**, 288, 358		1
5	Autoantibodies to pyruvate dehydrogenase complex in patients with systemic sclerosis. Possible role of anti-E1 alpha antibody as a serologic indicator for development of primary biliary cirrhosis. *Arthritis and Rheumatism*, **1995**, 38, 985-9		20
4	Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. *Arthritis and Rheumatism*, **1994**, 37, 391-4		104
3	Diagnostic significance of nailfold bleeding in scleroderma spectrum disorders. *Journal of the American Academy of Dermatology*, **1993**, 28, 198-203	4.5	23
2	Antihistone antibodies in patients with localized scleroderma. *Arthritis and Rheumatism*, **1993**, 36, 1137-41		136
1	Parabiotic Experiments on the Development of Neurohypophysis (With Bufo vulgaris formosus). *Okajimas Folia Anatomica Japonica*, **1959**, 32, 313-317_3	0.3	